Serious concerns have been raised regarding poor quality chemotherapy in several countries with which the CCLG Global Child Cancer group have partnerships. This includes asparaginase and other oncology drugs essential for treating children with cancer.
Aims of the meeting:
- Share lived experience and evidence of drug quality issues
- Discuss pharmacological, clinical and operational implications
- Propose actionable solutions to support partner centres
- Develop a practical roadmap for future work
Presenters:
- Prof Girish Chinnaswamy, Tata Memorial Hospital, Mumbai, India
‘Experience from India and the National Cancer Grid. Testing of chemotherapeutic agents, biologics, PK studies, and procurement processes. Challenges in identifying reliable manufacturers. Importance of random testing and pharmacovigilance’
- Dr Barry Goldspiel, PharmD, President, International Society of Oncology Pharmacy Practitioners (ISOPP), USA
‘The Oncology Pharmacy Society’s Perspective on Drug Quality Issues’
- Hannah E. Sauer, PharmD, St. Jude Global Pharmacy Program, Department of Global Pediatric Medicine, St. Jude Children’s Research Hospital, Memphis, USA
‘Strengthening Access to Quality Childhood Cancer Medicines: Emerging Insights from a Global Platform’
- Expert-led discussion and Q+A
